Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

As the pharma patent cliff approaches, delve into which important drug are about to lose exclusivity and how the industry is reacting.

Conservative commentator Scott Jennings had told a CNN panel that adding Ozempic instead of fluoride in public water systems can fix US' low birth rate ...

Novo Nordisk’s CEO says compounded GLP-1 knockoffs sourced from overseas ingredients could endanger patients and undermine ...

Despite their huge popularity, GLP-1 injury lawsuits citing the drugs as a cause for a host of severe GI issues and even ...

When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...

People taking GLP-1 weight loss drugs could be at risk of an ages-old disease, a new study has warned. New research has highlighted an unexpected potential health impact of weight loss drugs such as ...

Drug maker Novo Nordisk has filed a lawsuit against telehealth provider Hims and Hers over alleged copycat versions of its weight-loss and obesity medications.

Presented by the Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Legal pressures ...

After thyroidectomy, older patients faced small but higher rates of recurrent laryngeal nerve injury, postoperative hematoma, and mortality compared with younger patients, a meta-analysis reported. ( ...

Pharmaceutical giant Novo Nordisk announced Monday it is suing telemedicine platform Hims & Hers for allegedly “deceiving ...

The maker of Ozempic and Wegovy is suing a rival firm for selling what it says are "unsafe, knock-off" versions of its weight ...